| Theme | Interferon-free Treatment of Hepatitis C | |
|---|---|---|
| Title | Antiviral Therapies for Patients Infected with HCV—genotype 2 | |
| Publish Date | 2016/10 | |
| Author | Naoya Sakamoto | Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University |
| Author | Goki Suda | Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University |
| Author | Hiroshi Ogawa | Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University |
| Author | Kenichi Morikawa | Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University |
| [ Summary ] | Patients infected with HCV genotype 2 have long been treated with pegylated interferon plus ribavirin therapy. In 2015, an interferon‒free regimen for HCV genotype 2 was approved in Japan. Administration of a nucleotide polymerase inhibitor, sofosbuvir, in combination with ribavirin for 12 weeks was shown to eliminate the virus in 96 % of treated patients with few adverse events. | |